Ringene Biopharma

Ringene Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to developing innovative precision oncology therapies. Founded in 2017, the company leverages a structure-based drug discovery platform to target key signaling nodes within the RTK-RAS-MAPK pathway, aiming to overcome drug resistance in cancer patients. Its clinical pipeline features three primary candidates: RG001, a SHP2 allosteric inhibitor advancing into Phase 2 for solid tumors; RG002, a pan-FGFR inhibitor in Phase 1; and RG003, a BET inhibitor in Phase 1 for myelofibrosis. Ringene is supported by leading venture capital firms, including SDIC Venture Capital and Shenzhen Capital Group, and maintains strategic research partnerships with organizations like Medicilon.